Standardized natural ingredient discovery, chemical profiling, and compliant contract validation services engineered for global pharmaceutical and botanical developers.
Decarbonizing active pharmaceutical ingredient (API) synthesis and botanical extraction is no longer an optional ESG showcase—it is a critical criterion for international market access and Scope 3 supply chain survival.
Traditional extraction relies on massive volumes of petroleum ethers, ethanol, and chlorinated solvents that generate toxic VOC burdens. MedGence integrates closed-loop CO2 supercritical fluids and subcritical aqueous fractionation, eliminating hazardous volatile wastes while maintaining molecular fidelity of sensitive thermolabile polyphenols.
Our zero-waste operational paradigm extracts primary therapeutic markers (such as ginsenosides or flavonoids) before repurposing the cellular lignocellulosic pomace into prebiotic polysaccharides, organic agricultural biochar, or fungal fermentation substrates. This converts industrial waste streams into circular economic assets.
Concentration and drying represent over 64% of total energy consumption in natural medicine manufacturing. By implementing Mechanical Vapor Recompression (MVR) and continuous low-temperature vacuum evaporation, our operations recover up to 82% of latent steam enthalpy, drastically cutting fossil thermal loads.
Harnessing advanced digitalized batch records, AI-driven process optimization, and direct access to geo-authentic herb origins (Daodi) for total quality certainty.
Real-time near-infrared (NIR) sensors and inline liquid chromatography monitor phytochemical elution continuously. Neural networks adjust solvent flow rates, column bed temperatures, and agitation speeds dynamically to preserve batch-to-batch chemical fingerprint uniformity.
Located at the crossroads of major botanical production corridors in Hunan, MedGence leverages deep partnerships across China’s geo-authentic sourcing belts. Every raw batch is indexed with GPS harvest coordinates, weather anomalies, soil heavy metal metrics, and chromatographic fingerprints.
Bridging benchtop CRO assay design directly with CDMO commercial assets, our manufacturing network handles small pilot-scale trials (50 kg) to continuous multi-ton industrial outputs. This eliminates the frictional transfer errors typical between disparate lab vendors and contract packers.
Multinational dietary supplement brands, pharmaceutical licensors, and clean-label cosmetic innovators demand verifiable compliance, risk mitigation, and non-disclosure fidelity.
We provide verified Life Cycle Assessment (LCA) data packages detailing carbon dioxide equivalent (kg CO2e) per kilogram of delivered botanical extract. This enables Tier-1 international buyers to substantiate ESG filings with verifiable Scope 3 upstream accounting.
Raw botanicals face rigorous screening: over 500 multi-residue pesticide screens (GC-MS/MS, LC-MS/MS), heavy metals testing (ICP-MS for Pb, Cd, As, Hg), mycotoxins, irradiation screening, and ethylene oxide (EtO) verification meeting stringent European and US pharmacopeias.
All contract operations follow an entrusted research model protected by bilateral NDAs. We maintain air-gapped laboratory data silos and segregated cleanroom batching to prevent cross-contamination or unauthorized process leakages.
Navigating regional divergence across US FDA, EMA, Health Canada, and NMPA requires robust technical documentation and cross-jurisdictional validation.
Our QA dossiers comply directly with FDA cGMP criteria for dietary supplements and botanical drug products. We furnish comprehensive Chemistry, Manufacturing, and Controls (CMC) packages, process validation studies, and stability documentation under accelerated ICH zones.
We provide analytical alignment with European Pharmacopoeia (Ph. Eur.) monographs, supporting Well-Established Use (WEU) or Traditional Herbal Medicinal Product (THMPD) registrations with detailed chromatographic fingerprints (HPTLC/HPLC).
Safety claims are supported by GLP-compliant in vitro assays and animal safety profiles (LD50, 90-day repeat dose, Ames mutagenicity, micronucleus assays) acceptable to international health authorities for Novel Food, GRAS, and NDI filings.
Our engineering pathway toward circular, bio-synthetic, and zero-carbon extraction ecosystems by 2030.
Conversion of auxiliary utility boilers to industrial heat pumps powered by rooftop photovoltaic arrays, cutting operational natural gas reliance by 45%.
Deployment of fractional cryogenic condensing and zeolitic membrane pervaporation units to virtually eliminate fugitive ethanol releases during mass extraction.
Targeted structural modification using immobilized enzymatic biocatalysts to convert low-potency precursor ginsenosides into ultra-rare Rh2 and Rg3 without acid catalysts.
Blockchain-anchored batch emission telemetry feeding real-time digital twins of every CDMO batch run for instant client ESG disclosure compliance.
From active raw fractions to multi-format retail packaging—explore certified OEM supply chains manufactured under documented environmental stewardship.
Addressing the operational, analytical, and sustainability queries of biopharmaceutical sourcing leaders.
